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SUMMARY. Dengue is the most common arthropod-
borne infection worldwide, affecting at least 50 million
people every year and endemic in more than 100
countries. The dengue virus is a single-stranded RNA
virus with four major serotypes. Infection with one
serotype confers homotypic immunity but not heterolo-
gous immunity, and secondary infection with another
serotype may lead to more severe disease. The major
route of transmission occurs through the Aedes aegypti
mosquito vector, but dengue has also been transmitted
through blood transfusion and organ transplantation.
Infection results in a spectrum of clinical illness ranging
from asymptomatic infection, undifferentiated fever,
dengue fever, dengue haemorrhagic fever (DHF) to
dengue shock syndrome (DSS). Dengue is spreading
rapidly to new areas and with increasing frequency of
majoroutbreaks.Atrendhasalsobeenobservedtowards
increasing age among infected patients. This will impact
blood supply availability as more blood donors are
deferred because of dengue infection or exposure to
infection.Theriskoftransmissionthroughtransfusionof
blood from asymptomatic viraemic donors will also
increase. Although screening tests for dengue and effec-
tive pathogen reduction processes are now available for
the blood supply, the value of implementing these costly
measures needs to be carefully considered. Demand for
platelets and fresh frozen plasma will rise with increasing
numberofDHF/DSS.Evidence-based guidelinesforthe
clinical use of these blood components in the manage-
ment of patients with DHF/DSS have not been well
established, and inappropriate use will contribute to the
challenges faced by blood services.
Key words: blood supply, dengue fever, dengue virus.
The World Health Organization classifies dengue as
a major international public health concern. Some 25
billion people or two-fifths of the worlds population
are at risk of infection. Dengue haemorrhagic fever
(DHF)isendemicinmorethan100countriesinAfrica,
the Americas, Eastern Mediterranean, South-East
Asia and the Western Pacific regions (World Health
Organization, 2008).
Worldwide, it is estimated that 50 million dengue
infections occur every year with 500 000 requiring
hospitalization;25%ofthoseaffectedmaydie(World
Health Organization, 2008). These figures are likely to
be underestimated as the numbers reported are
influenced by different surveillance and reporting
systems as well as varying interpretations of case
definitions and the presence of missed and silent
infections (Guha-Sapir & Schimmer, 2005).
EPIDEMIOLOGY
Prior to the 1940s, dengue was characterized by
epidemics that occurred relatively infrequently, and
generally, each location involved a single viral
serotype. When sufficient numbers of vectors and
susceptible hosts for the particular serotype were
reached, a sudden sharp rise in transmission occurred.
In contrast, the predominant pattern of global trans-
mission today is hyperendemic dengue, where there is
continuous circulation of multiple viral serotypes
withinaconstantpoolofsusceptiblehostsandvectors.
The first known epidemic of DHF in Asia occurred in
Manila, Philippines in 1953–1954, to be followed by
Bangkok, Thailand in 1958 and Malaysia, Singapore
and Vietnam in the 1960s. With the economic boom and
associatedurbanization,itrapidlyspreadtoinvolvemost
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become the leading cause of hospitalization and death
among children in the region. Increased spread is also
seen into suburban and rural areas (Gubler, 2002).
In the Americas, with the eradication of A. aegypti
vectortocontrolyellowfever,onlysporadiccaseswere
reported until the early 1980s when a large outbreak
occurringinCubamarked thestartofepidemicspread
to the Pacific and the American tropics. Dengue has
been prevalent in tropical Africa, although DHF is
rare. It occurred occasionally in the temperate regions
of North Africa and the Mediterranean regions until
the 1990s when epidemics were reported in the
Comoros. Dengue continues to expand its territory,
and the only continents that currently do not
experience dengue transmission are Europe and
Antarctica.
The factors that have contributed to the dramatic
expansion of dengue include population growth,
urbanization, inadequate water management, lack of
effective mosquito control and convenient global
travel. In the last few years, changes in weather
patterns may have contributed to the expansion in
the habitat range of the mosquito vector. Increased
epidemic activity may also increase the rate of viral
genetic change and emergence of strains or genotypes
with greater epidemic potential (Gubler, 1998; Messer
et al., 2003; Dash et al., 2006).
Although DHF is primarily an illness of children,
surveillance studies in recent years in several countries
have reported increasing age among infected patients
(Liu et al., 2003; Gupta et al., 2006; Khan et al., 2007;
Ooietal.,2006).InSingapore,thishasbeenascribedto
lowered herd immunity in the population as a result of
reduced dengue in the 1970s and 1980s. Studies have
shown that A. aegypti bites adults more frequently
thanchildren(DeBenedictisetal.,2003),andtogether,
these could explain the higher incidence rate among
young adults in Singapore.
DENGUE VIRUS AND THE MOSQUITO
VECTOR
The dengue virus is a single-stranded RNA virus
belonging to the Flaviviridae family. The viral genome
isapproximately11 kbinlengthandissurroundedbyan
icosahedral nucleocapsid covered by a lipid envelope.
Thematurevirionhasthreestructural(core,membrane-
associatedandenvelope)andsevennon-structural(NS1,
NS2a, NS2b, NS3, NS4a, NS4b and NS5) proteins.
The envelope protein is involved in the main
biological functions and is responsible for binding and
transport into host cells. It is also associated with the
induction of neutralizing antibodies and development
of protective immune response in the host. The non-
structural proteins are expressed as both membrane-
associatedandsecretedformsandhavebeenimplicated
in the pathogenesis of severe disease (Gubler, 1998).
Therearefourserotypesclassifiedaccordingtotheir
immunological properties – DEN-1, DEN-2, DEN-3
and DEN-4. Infection with one dengue serotype
confers lifelong immunity against that serotype but
only transient protection against infection by other
serotypes.Allfourserotypeshavebeenassociatedwith
outbreaks, having seen DEN-2 as the predominant
serotype of primary infection during the outbreak in
2005 (Savage et al., 1998; Messer et al., 2003; Gupta
et al., 2006; Ooi et al., 2006). Recent data have also
demonstrated that the various genotypes within
each serotype possess varying epidemic potential
(Anderson & Rico-Hesse, 2006).
The primary vector for the dengue virus is the
A. aegypti mosquito, although the virus may be trans-
mittedbytheAedesalbopictusandAedespolynesiensisas
well. Infected humans are the main carriers and ampli-
fication host of the dengue virus. Female mosquitoes
acquire the virus by biting infected humans in the
viraemic phase and become infective after an extrinsic
incubationperiodof7–14 days.Subsequently,the mos-
quito may transmit the virus during every feeding. The
lengthoftheextrinsicincubationperiodisdependenton
theambienttemperatureandthevirusinvolved,bothof
whichaffectthereplicationrateofthevirusinthevector.
Aedes aegypti is a highly domesticated mosquito that
breedsinartificialcontainerssuchaswaterstoragetanks,
subterranean pits, flowerpot trays and other ornamental
containers. The vector is known to prefer to rest indoor,
although studies have shown that they may seek ovi-
position outdoors. Peak biting activity is at dawn and
dusk.ThemultiplefeedingbehaviourofA. aegyptiandits
preference for human hosts are believed to contribute to
theexplosivespreadofdenguevirus,eveninthepresence
of a low A. aegypti population (Scott et al., 1997).
LABORATORY DIAGNOSIS
Laboratory diagnosis of dengue can be performed by
viral isolation, serological tests, dengue antigen tests
and molecular detection.
Virus isolation for dengue is performed by inocula-
tionofthesampleintolivemice,livemosquitoesorcell
cultures. Successful detection of virus may be affected
by the presence of interfering antibodies and the heat-
labile nature of the virus. It is normally used as
a confirmatory test, being impractical for diagnosis or
screening on a large scale.
Dengue-specificimmunoglobulinM(IgM)andimmu-
noglobulin G (IgG) enzyme-linked immunosorbent
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relativelyinexpensive,hasgoodsensitivityandisquick
and easy to perform. IgM is detectable at 3–5 days
after infection, peaks at about 2 weeks and declines to
undetectable levels over 2–3 months. IgG becomes
elevated after 9–10 days and persists at detectable
levels for life. During secondary infection, IgG
increasesrapidlytomuchhigherlevelswithin1–2 days
after infection. Because the virus shares antigenic
epitopes with other flaviviruses, the presence of cross-
reactive antibodies may interfere with serological
diagnosis (World Health Organization, 1997).
The dengue NS1 antigen-capture ELISA is useful
for detection of dengue early in the disease. The test
sensitivity has been demonstrated to be significantly
higher in primary dengue infection (973%) than in
secondary dengue infection (700%), with a positive
predictivevalueof100%andnegativepredictivevalue
of 973% (Kumarasamy et al., 2007). Although it is
usefulinthefirstweekofdiseaseandprovidesevidence
of presence of the virus, its effectiveness in screening
blood donors has not been established yet.
Like the NS1 test, the dengue RNA test detects viral
material that is typically present in the first 5 days of
disease. The advantages of the test are good sensitivity
and specificity, and the ability to rapidly detect minute
quantities of dengue virus material in serum. The dis-
advantages are the relatively high cost and expertise
needed, particularly proper quality control to avoid
false positives.
Real-time reverse transcription–polymerase chain
reaction (RT-PCR), using either a universal dengue
oligonucleotide primer pair or a combination of the
four serotype-specific oligonucleotide primers, is
widely used for clinical diagnosis and public health
surveillance. It has established detection limits of
01 plaque-formingunits(PFU) mL
21forDEN-1and
DEN-2, 1 PFU mL
21 for DEN-3 and 001 PFU
mL
21 for DEN-4 and 88% correlation with virus
isolation (Lai et al., 2006).
Group-specific one-step PCR using universal den-
gue oligonucleotide primer pairs and SYBR green I is
widely used for population surveillance as it is fast and
cost-effectiveformass screening,withadetectionlimit
of10–41 PFU mL
21(Shuetal.,2003;Laietal.,2006).
A prototype dengue RNA transcription-mediated
amplification (TMA) assay (Gen-Probe, Inc., San
Diego, CA, USA) was developed for use in large-scale
screening of blood donor samples and uses target
genomic sequences thatare highly conserved acrossall
four serotypes. The analytical sensitivity of the assay
has been established at a detection of 149 copies
mL
21 at 95% detection limit and 35 copies mL
21 at
50% detection limit for DEN-1, with comparable
sensitivity for all four serotypes, and with a specificity
of 9991% (Linnen et al., 2008).
CLINICAL FEATURES
Dengue infection can produce a spectrum of clinical
illness – undifferentiated fever, dengue fever (DF),
DHF and dengue shock syndrome (DSS). In infants
and children younger than 15 years, the patient is
usually either asymptomatic or has a mild undifferen-
tiated febrile illness with maculopapular rash.
DF is characterized by the sudden onset of high
fever, severe headache (especially in the retro-orbital
area), arthralgia, myalgia, nausea, vomiting and rash.
Infants and younger children tend to present with an
undifferentiated febrile disease, often with rash. The
acute febrile illness lasts approximately 2–7 days.
DHF is clinically defined by high fever, haemor-
rhagicmanifestations,thrombocytopeniaandevidence
of plasma leakage (Table 1). Four grades of severity
Table 1. World Health Organization case definition for
DHF and DSS*
Case definition for DHF
The following must be present:
Fever or history of acute fever lasting 2–7 days,
occasionally biphasic
Haemorrhagic tendencies, evidenced by at least one
of the following:
A positive tourniquet test
Petechiae, ecchymoses or purpura
Bleeding from the mucosa, gastrointestinal tract,
injection sites or other locations
Haematemesis or melaena
Thrombocytopenia (100 000 cells mm
23 or less)
Evidence of plasma leakage because of increased vascular
permeability, manifested by at least one of the following:
A rise in the haematocrit equal to or greater than 20%
above average for age, sex and population
A drop in the haematocrit following volume
replacement treatment equal to or greater than 20%
of baseline
Signs of plasma leakage such as pleural effusion, ascites
and hypoproteinaemia
Case definition for DSS
All the above four criteria for DHF must be present plus
evidence of circulatory failure manifested by:
Rapid and weak pulse
Narrow pulse pressure [<20 mmHg (27 kPa)]
Or manifested by:
Hypotension for age
Cold, clammy skin and restlessness
*From World Health Organization (1997).
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are considered to be DSS. The presence of thrombo-
cytopenia with concurrent haemoconcentration differ-
entiates grades I and II DHF from DF (World Health
Organization, 1997). Clinical deterioration usually
occurs towards the end of the febrile phase when the
patient progresses to the phase of plasma leakage.
Plasma leakage manifests as tachycardia, hypoten-
sion, pleural effusions and ascites develop. Bleeding
from the gastrointestinal tract or epistaxis may occur,
with menorrhagia in females. Epigastric discomfort,
myalgia, vomiting, diarrhoea and abdominal pain are
commoninadults.Tenderhepatomegalyisobservedin
all patients and splenomegaly in some. Shock, plasma
leakage and marked thrombocytopenia are more
common in children, whereas internal haemorrhage is
morefrequentasageincreases(Hammondetal.,2005).
In DHF, the decline in platelet counts tends to
precede plasma leakage, and platelet counts and
packed cell volume are often used to monitor for
impending deterioration (Tai et al., 1999). Haemocon-
centration may be difficult to ascertain in areas where
a significant proportion of the population carries the
thalassaemia genetic trait or where there is a high
degree of iron deficiency (Khan et al., 2007).
DSS is a medical emergency associated with very
high mortality. Severe plasma leakage results in
prolonged shock, accompanied by metabolic acidosis,
which in turn precipitates disseminated intravenous
coagulation (DIC). Massive haemorrhage or enceph-
alopathy may develop, the former requiring intensive
blood transfusion support.
Severe dengue infections can result in complica-
tions such as liver failure, DIC, encephalopathy,
myocarditis, acute renal failure and haemolytic-
uraemic syndrome. These are generally rare and
usually seen in patients with DHF grades III and IV
(Malavige, 2006).
There are no specific drugs against the dengue virus,
and management is symptomatic and supportive. DF
is typically a self-limiting disease with a mortality rate
of less than 1%, although the convalescent phase may
sometimes be prolonged in adults. Successful manage-
ment of DHF lies in proper management of fluid
balance. Early identification of the plasma leakage
phase with prompt resuscitation has been shown to
reduce complications and improve outcome. When
adequately treated, the mortality rate for DHF can be
as low as 1%, but if untreated, it can exceed 20%
(World Health Organization, 1997, 2008).
PATHOPHYSIOLOGY
The primary pathophysiology seen in DHF is an acute
increase in vascular permeability that leads to leakage
of plasma into the extravascular compartment, result-
ing in haemoconcentration and decreased blood
pressure. Increased vascular permeability is shown to
result from endothelial gaps in the peripheral vascular
bed. No necrotic or inflammatory lesions are seen,
suggestingthatthechangesarefunctionalandlikelyto
be caused by a short-acting mediator.
The principal mechanisms by which dengue virus
infection causes DHF are still not clearly elucidated
and are believed to be a result of viral and host factors
that involve the activation of T cells, production of
cytokines/chemokines and disturbance of the haemo-
static system. These result in the release of other
cytokines that mediate the systemic effects of plasma
leakageandcirculatoryinsufficiency.Inaddition,there
is evidence for increased apoptosis and endothelial cell
dysfunction (Gubler, 1998; Guglani & Kabra, 2005).
More severe infection is observed to occur in
secondary infection than in primary infection
(Pancharoen et al., 2001). Various theories have been
put forward to explain this observation, including the
phenomenon of antibody-dependent enhancement
and more recently the theory of original antigenic sin
(Mongkolsapaya et al., 2003).
During the early stage of infection, thrombocytope-
nia occurs as a result of bone marrow hypocellularity
resulting from direct dengue infection of haemato-
poietic progenitor cells and stromal cells (Nakao et al.,
1989). As the fever settles, bone marrow hyper-
cellularity is seen, and increased destruction from
immune-mediated clearance of platelets becomes the
primary mechanism for thrombocytopenia (Mitrakul
et al., 1977).
Table 2. World Health Organization grading severity of
DHF*
Grade I Fever accompanied by nonspecific
constitutional symptoms; the only
haemorrhagic manifestation is a positive
tourniquet test and/or easy bruising
Grade II Spontaneous bleeding in addition to the
manifestations of grade I patients, usually
in the forms of skin or other haemorrhages
Grade III Circulatory failure manifested by a rapid,
weak pulse and narrowing of pulse
pressure or hypotension, with the presence
of cold, clammy skin and restlessness
Grade IV Profound shock with undetectable blood
pressure or pulse
*From World Health Organization (1997).
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There are age-related differences in susceptibility to
DHF/DSS. Although children infected with dengue
virus tend to manifest milder clinical symptoms than
adults, they have higher risk of developing DHF/DSS
(Hammondetal.,2005;Ooietal.,2006).Itispostulated
that children have a greater propensity for vascular
leakage under normal physiological conditions than
adults, and this results in less ability to accommodate
additional factors that increase vascular permeability.
Hospitalization and death rates for severe and very
severedenguearehighestinthoseyoungerthan15 years
and those older than 60 years (Guzma ´ n et al., 2002).
Elderly patients older than 65 years are more likely
to develop severe illness, with higher risk of hospital-
izationanddeathwheninfectedwithdenguevirusthan
youths and younger adults (Garcı´a-Rivera & Rigau-
Pe ´ rez, 2003). Age above 65 years, history of dengue
infection, diabetes mellitus, hypertension and renal
insufficiencyhavebeenidentifiedasbeingsignificantly
associated with DHF/DSS (Lee et al., 2006).
Genetic influences, including human leucocyte
antigen allele associations, may play a part in disease
susceptibility and severity (Wagenaar et al., 2004). In
Haiti, very few DHF cases are recorded despite
a transmission rate of 30% and evidence showing the
presence of all four serotypes in the population
(Halstead et al., 2001). There is similar paucity of
DHF cases in Africa despite the presence of dengue
virus in the population, suggesting the presence of
a dengue resistance gene.
VIRAEMIA AND TRANSMISSION
Theprimarymodeoftransmissionforthedenguevirus
occurs through the mosquito vector. After the bite of
aninfected mosquito, the dengue virus enters the body
and replicates within the cells of the mononuclear
phagocyte lineage. There is usually an incubation
period of 3–14 days (average 4–7 days). The period of
viraemia roughly corresponds to the period of fever,
peaking at the time of or shortly after onset of illness
andremainingdetectableforvariousperiods(typically
2–7 days). There is no correlation between the
duration of viraemia and serotype. Some studies have
reported correlation between viraemia and disease
severity, whereas others report no correlation (Gubler
et al., 1981; Vaughn et al., 1997; Murgue et al., 2000).
Infectivity during the incubation period has not been
well defined, partly because of the lack of an animal
model for dengue. In studies involving human volun-
teersduringthe1920s,clinicallyapparentDFresultedin
80and25%ofbitingexperimentsat1and2 daysbefore
theonsetoffever,indicatingthatinfectedpersonscould
transmit virus as early as or even earlier than 2 days
before symptoms develop (Nishiura & Halstead, 2007).
Vertical transmission has been reported, with intra-
partum transmission in at least two cases where the
onset of neonatal illness developed on the first day of
life (Sirinavin et al., 2004) and one case involving
a mother who was diagnosed with DHF just prior to
delivery (Rigau-Pe ´ rez et al., 2001).
Nosocomialtransmissionthroughneedlestickinjury
and mucocutaneous exposure has also been reported.
The case of mucocutaneous transmission involved
a healthcare worker who developed dengue infection
after blood from a febrile-dengue-infected traveller
splashed onto her face (Chen & Wilson, 2005).
Transmission of dengue infection has been reported
from donor to recipient in one case of living donor
renal transplant (Tan et al., 2005). The clinical presen-
tation and course of illness was similar to that of an
immunocompetent patient, except for prolonged
course of illness (19 days) and duration of thrombo-
cytopenia (12 days).
Transmission during a bone marrow transplant was
reported in one instance during a dengue epidemic in
Puerto Rico in 1994 (Rigau-Pe ´ rez et al., 2001). The
bonemarrowrecipientdevelopedfever4 daysafterthe
transplant and subsequently died. The donor devel-
oped fever and headache 2 days after the marrow was
harvested.
There are only two reported instances of trans-
mission through blood transfusion. The first involved
a patient in Hong Kong who developed fever 3 days
after a blood transfusion, associated with moderate
neutropenia, severe thrombocytopenia and hypoten-
sion responsive to fluid therapy. The donor was
asymptomatic at the time of donation but developed
mild symptoms of DF 1 day after blood donation. An
archivedsample from the donation alsotested positive
for dengue virus by RT-PCR (Chuang et al., 2008;
C. K. Lin, Hong Kong Red Cross Blood Transfusion
Service, Hong Kong, pers. comm.).
Thesecondinvolvedthetransmissionofdenguefrom
anasymptomatic blooddonorwhodevelopedanacute
febrile illness the day after donating blood. Look back
investigation confirmed dengue infection in the recip-
ients of the three blood products from his donation.
TworecipientshadDFwith some evidence ofcapillary
leakage, whereas the platelet recipient had asymptom-
atic seroconversion. All recovered without sequelae. A
stored serum sample from the donation tested positive
for DEN-2 by RT-PCR (Tambyah et al., 2008).
The small number of reports of transfusion trans-
missioncouldbebecauseofthefactthatitisdifficultto
differentiate between non-mosquito transmission and
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vector is widespread. Many infections may also result
in mild or asymptomatic illness that is not recognized
as transfusion-acquired infection, and diagnostic
laboratories to document infections and their sources
are often not available in many endemic countries
(Chen & Wilson, 2005).
ASYMPTOMATIC INFECTION
Various studies have shown the presence of asymp-
tomatic or subclinical infection, which can range from
077 to87% dependingonthe populationstudied (Ooi
et al., 2006). It is estimated that for every one
symptomatic case, there can be 67 cases that are
asymptomatic (Chen & Wilson, 2005). There is no
correlation with total dengue incidence, hospitaliza-
tion rates, age or sex, although one study found silent
transmissiontooccurmorecommonlyinthe15-to40-
year-old age group.
In a study of 329 healthy volunteers in a province in
Thailand with high rate of dengue infection, 29 (88%)
had a serum sample positive for dengue IgM, of which
two samples tested positive for viral RNA (Poblap
et al., 2006). Cluster sampling studies around index
cases in Indonesia detected eight post-enrolment
asymptomatic dengue infections of 785 volunteers
over a 2-year period, of which two demonstrated
viraemia by RT-PCR (Beckett et al., 2005). Virus was
isolated in 215 of 3189 (67%) persons in a study
evaluating the dynamics of transmission of dengue
virus in a dengue epidemic area of Colombia; most of
whom were asymptomatic (Me ´ ndez et al., 2006).
Two recent studies reported viraemia in blood
donations collected from four countries experiencing
high dengue transmission rates. In the first study, 12
(007%) of 16 521 blood donations collected in Puerto
Rico tested positive using the dengue-specific TMA
nucleic acid amplification test (NAT) (Mohammed
et al., 2008). Supplemental testing using RT-PCR was
positive in four samples (viral loads 2  10
3 to
8  10
7 copies mL
21), and live virus was recovered
from three of the PCR-positive samples.
In the second study, samples from asymptomatic
blood donors in Honduras, Brazil and Australia were
obtainedduringperiodsofclinicaldengueoutbreaksand
screened using the dengue-specific TMA assay (Linnen
et al., 2008). Nine (030%) of 2994 Honduran samples
tested positive, of which 8 were confirmed by RT-PCR
(viral loads 3  10
4 to 42  10
4 copies mL
21)a n d4
samplesyieldedinfectiousviruses.Three(006%)of4858
Brazilian samples tested positive, of which 2 were RT-
PCRpositive(viralloads12and294 copies mL
21);viral
isolation was not performed for these samples.
IMPACT ON BLOOD DONORS
Dengue isspreading rapidly into newareas, and major
outbreaks are occurring with greater frequency. More
than half the world is now endemic for dengue, and
there is increasing likelihood that blood donors in
these countries will be infected orexposed toinfection.
As the numbers continue to increase, the effect on
blood donor attendance will reach levels sufficient
enough to impact significantly on the blood supply.
In most countries, donors who have been infected
with dengue virus are deferred for periods of up to
6 months(Table 3)orevenlongeriftheyhavereceived
blood transfusions. Blood donors who donate regu-
larly will be particularly affected, including apheresis
donors who may donate as often as 12 or 13 times
a year. Healthy uninfected donors whose family
members or working colleagues are infected with
dengue are also likely to be deferred from donating
blood. These donors would also have less time
available to donate blood, as they would need to care
for sick family members or take on increased work
responsibilities as a result of more workplace illness.
Table 3. Dengue and donor deferral
Country Donor deferral measures for dengue
Singapore* 6 months deferral for history of dengue
infection
3 weeks deferral for history of fever
No travel-related deferral for dengue
Hong Kong* 6 months deferral for history of dengue
infection
2 weeks deferral for history of fever
No travel-related deferral for dengue
Sri Lanka* No specific deferral for history of dengue
infection
2 weeks deferral for history of fever
No travel-related deferral for dengue
Australia† 4 weeks deferral for history of dengue
infection
No travel-related deferral for dengue
New Zealand‡ 4 weeks deferral for history of dengue
infection
No travel-related deferral for dengue
UK‡ 2 weeks deferral for history of dengue
infection
No travel-related deferral for dengue
United States‡ 4 weeks deferral for history of dengue
infection
No travel-related deferral for dengue
*Endemic for dengue.
†Non-endemic except parts of Northern Australia.
‡Non-endemic.
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do not donate blood. As this trend reverses and the
modal age of infection increases, dengue will increas-
ingly affect the segment of population that do donate
blood – youths and young adults – further reducing
blood donor availability. The annual incidence of
dengue infection in Singapore was 1806 per 100 000
population in 2007, with highest incidence in the
segment of population older than 15 years. It is
estimated that dengue infection has reduced the
blood donor pool by 02%; this excludes donors
deferredfor symptoms related todengueandexposure
to dengue, which is estimated to lose a further 11% of
donors in 2007.
RISK OF TRANSFUSION-TRANSMITTED
DENGUE
Increased prevalence in the population increases the
risk that blood will be collected from a viraemic donor
during the asymptomatic or subclinical phase of
infection. Transmission of dengue through blood
collected from asymptomatic donors has been dem-
onstrated in the two reports from Hong Kong and
Singapore, both occurring during the height of
epidemics in these countries (Chuang et al., 2008;
Tambyah et al., 2008). Blood services in countries
experiencing dengue epidemics will need to decide
whether stronger measures are needed to protect the
blood supply.
During infectious disease outbreaks such as dengue,
severe acute respiratory syndrome (SARS) and chi-
kungunya disease, most countries have adopted risk
reduction strategies that focus on excluding donors
who may be at higher risk of infection or who may be
exhibiting early symptoms of infection. In the case of
dengue, this has relied mainly on questioning the
donor for a recent history of travel to outbreak areas
and for symptoms of fever, rash or malaise.
The relatively low sensitivity and specificity of
blood safety measures based on donor history has
long been debated. Travel-related deferrals in partic-
ular lead to high rates of unnecessary donor deferral.
In addition, there is often a negative effect on the
donor of being deferred, and many donors do not
return even if the deferral is temporary (Halperin
et al., 1998). Introducing such measures during
outbreaks of dengue is likely to exacerbate the
problems of dwindling donor attendance and
decreasing blood collection described earlier. For
example, in Singapore, the SARS outbreak in 2003
and chikungunya outbreak in 2008 resulted in donor
deferral rates of 4 and 3%, respectively.
In a population where dengue is endemic, exclusion
on the basis of symptoms also fails to address the risk
of collecting blood from asymptomatic viraemic
donors. Studies so far suggest that there is at least
a 1–2 days period of infectivity prior to the develop-
mentofsymptoms.Thepresenceofdengueviraemiain
asymptomaticpersons, includingblood donors,iswell
documented during dengue epidemics.
The efficiency of transmission depends on a combi-
nationoffactors:amountandstabilityofvirus,volume
of viraemic blood transfused and immune status of the
recipient.Althoughdengueviraemiatitresinvertebrate
hosts are usually in the range of 10
5–10
9 copies mL
21
(Chen & Wilson, 2005), it is likely that lower levels and
shorter duration of viraemia occur during asymptom-
aticinfection compared with DF or DHF. Mohammed
et al. (2008) and Linnen et al. (2008) demonstrated the
presence of viral loads of at least 2  10
3 to 8  10
7
copies mL
21 and 12to42  10
4 copies mL
21,r e s p e c -
tively, in healthy blood donors.
Experience with West Nile Virus (WNV) suggests
that not all positive donations are infectious. In these
two studies, live virus was recovered from 7 of 21
positivedonations,indicatingthatthesedonationswere
capableoftransmittinginfectiontorecipients.Theviral
loads present were in the order of 44  10
2 copies
mL
21 to 812  10
7 copies mL
21. In contrast, cell
cultures werenegative infivedonationswithviral loads
between 78 and 74  10
3 copies mL
21. Although this
suggeststhatlowerviralloadsareassociatedwithlower
risk of infectivity, WNV has been transmitted from
transfusions with estimated viral loads as low as
006 PFU mL
21 or 24 copies mL
21.I ti st h e r e f o r e
possible that larger volumes involved during blood
transfusion could still transmit infection despite lower
viral load concentrations.
The risk of infection will also depend on the size of
population exposed to the infection and immunity
because of prior infection. Infection may not occur if
the majority of individuals have previously been
infected and developed protective antibodies.
Studies on the prototype dengue NAT system
showed sufficient sensitivity and early detection to
enable interdiction of infective donations. However, it
is likely that individual sample NAT rather than mini-
pool NAT will be required for dengue screening
because of the relatively low levels of dengue RNA
(Mohammed et al., 2008). At the time of writing, at
least two dengue NAT systems for blood supply
screening are in development from Gen-Probe Ltd.
and Roche Diagnostics, Ltd., and it is possible that
these will be commercially available within the next
few years. While the cost of such systems is not
available as yet, it is unlikely that they will be less than
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(HBV-NAT).
Analternativestrategytotestingispathogenreduction,
which has the added advantage that it is effective against
other infections that can be transmitted through blood,
such as the chikungunya virus and WNV. Preliminary
studies using the amotosalen-HCl and long-wavelength
ultraviolet light (UVA) system on apheresis platelets
have shown effectiveness against the dengue virus (Lam
et al., 2007). Pathogen reduction technology is not yet
available for red cells, and this has somewhat limited its
impact. Nonetheless, as more vector-transmitted infec-
tions emerge to threaten the blood supply, pathogen
reduction of platelets and plasma coupled with selective
red cell inventory hold may be useful in reducing
transmission risks without unnecessary donor deferral.
Regardless of whether a new screening assay or
pathogen reduction method is selected, the recent
experience with human immunodeficiency virus NAT
(HIV-NAT) and hepatitis C virus NAT (HCV-NAT)
suggests that this will involve high costs and expensive
technicalexpertise(Marshalletal.,2004).Thereislittle
doubt that transfusion-transmitted infections will
represent only a small fraction of total infections
during an epidemic. In countries with high dengue
prevalence, the introduction of a screening test or
pathogen reduction process is therefore likely to
prevent infections through blood transfusion, but the
proportion would be low in comparison to the total
number of infections (Table 4).
Dengue carries a high economic burden on society,
in terms of medical costs and control measures, as well
Table 4. Options for minimizing dengue risk in the blood supply
Strategies Endemic countries Non-endemic countries
No specific measures taken for dengue Risk of transfusion-transmitted
dengue increased, dependent on
prevalence in donor population and
proportion of donors with
asymptomatic infection
Risk of transfusion-transmitted
dengue low, dependent on
proportion of donor population
who may recently be exposed to
dengue infection through travel
No direct cost to blood service, but
indirect cost from patient morbidity
from transfusion-transmitted
infection and loss of confidence in
blood supply safety
No direct cost to blood service, but
indirect cost from loss of confidence
in blood supply safety in event of
a transfusion-transmitted infection
occurring
Donor qualification – deferral of
at-risk donors, e.g. symptoms of
fever, travel history, exposure to
dengue patients, etc.
Deferral based on exposure not
feasible when disease is endemic,
unable to exclude early and
asymptomatic infection
Deferral based on exposure feasible,
able to reduce risk of accepting
donations from early and
asymptomatic infected donors
Nonspecific, leads to high donor loss Low donor loss, dependent on
proportion of donor population
likely to travel to endemic countries
Low cost-effectiveness Cost-effective
NAT testing of donations for dengue Able to detect asymptomatic infection Able to detect asymptomatic infection
Donor loss dependent on specificity of
test system
Donor loss dependent on specificity of
test system
Expensive Expensive
Cost-effectiveness depends on
prevalence of asymptomatic
infected donors
Low cost-effectiveness
Pathogen reduction Able to reduce transmission risks Able to reduce transmission risks
Expensive and only available for
platelets and plasma currently. May
result in reduced product yields
Expensive and only available for
platelets and plasma currently. May
result in reduced product yields
Low cost-effectiveness for dengue
alone
Low cost-effectiveness for dengue
alone
Increased cost-effectiveness depends
on ability to reduce risks of other
transfusion-transmitted diseases as well
Increased cost-effectiveness depends
on ability to reduce risks of other
transfusion-transmitted diseases as well
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Guha-Sapir & Schimmer, 2005). In developing coun-
tries with limited resources, the decision to implement
a costly risk reduction strategy into the blood supply
must take into consideration its cost-effectiveness in
reducing disease morbidity in relation to the overall
health situation in the country.
Cost-effectiveness of risk reduction strategies for
transfusion-transmitted diseases depends on the clin-
ical consequences on recipient health, and whether
infectionacquiredthroughbloodtransfusionresultsin
moreseriousdisease.Therearefewstudiesreportedon
theclinicaleffectsofsuperimposeddengueinfectionon
patients. A retrospective analysis in Brazil of primary
dengue infection in 27 renal transplant recipients
showed similar clinical picture and outcome as in the
general population (Azevedo et al., 2007). A report
from French Guiana of 22 pregnant women who had
DF during pregnancy found no abnormality in their
infants but observed a higher foetal death rate than
usual, suggesting that dengue infection might increase
the risk for foetal mortality (Carles et al., 1999).
Superimposed dengue may subject the patient to
additional risk. Tan et al. (2005) noted in their case
report that the occurrence of DHF early post-
operatively posed potential danger to the transplant
patient as a result of persistent haemorrhage from
cut tissue surfaces from the associated bleeding
diathesis. Most recipients of blood transfusion are
in the older age group and will therefore be at
increased risk of DHF and complications following
dengue infection. The higher risks to patients
involving secondary infection with a different sero-
type have also not been studied.
Case studies suggest that dengue acquired through
blood transfusion will not result in more severe illness
than that acquired through the usual vector routes of
transmission. The four patients who acquired infec-
tion through blood transfusion in Hong Kong and
Singapore experienced relatively benign course of
illness and uneventful recovery with no serious
sequelae. This could be because of the lower viral
loads present in the blood donations collected.
Nevertheless, more data will be needed to make a firm
conclusion.
DENGUE AND PLATELET
TRANSFUSIONS
Blood transfusion isonly indicated in cases where there
is significant clinicalbleeding. The exact platelet counts
atwhichplatelettransfusionsshouldbegivenindengue
infection are still not well defined, although most
clinical guidelines recommend that platelet transfu-
sions are given to patients who develop serious
haemorrhagic manifestations or have very low platelet
counts – platelet counts falling below 10–20  10
9 L
21
withouthaemorrhageor50  10
9 L
21withbleedingor
haemorrhage.
Inchildren,thereislittlecorrelationbetweenplatelet
count and bleeding manifestations or between platelet
countanddiseaseseverity(Malavige,2006).Astudyof
risk factors for haemorrhage in 114 paediatric patients
withDSSshowednocorrelationbetweenbleedingand
plateletcount,andprolongeddurationofshockwasin
fact the strongest risk factor for haemorrhage (Lum
et al., 2002).
Inadults,aplateletcountof5  10
9 L
21andpacked
cell volume >50 are significantly associated with the
presence of bleeding manifestations (Malavige, 2006).
However, in uncomplicated dengue patients, one study
of 120 patients found no difference in morbidity
between those with platelet counts above or below
50  10
9 L
21 with or without fever (Lye et al., 2008).
Another study of 245 dengue patients showed no
correlationbetweenclinicalbleedingandplateletcount,
and 81 non-bleeding patients had counts of less than
20  10
9 L
21 (Chaudhary et al., 2006). In contrast,
another study of 225 dengue patients suggested that
bleeding occurred more often in patients with platelet
counts below 20  10
9 L
21 (Makroo et al., 2007).
In a study of 106 paediatric patients with DSS with
thrombocytopenia and coagulopathy, there was no
significantdifferenceinhaemorrhagebetweenpatients
who received preventive transfusions compared with
those who did not. Patients who received transfusion
had higher frequency of development of pulmonary
oedema and increased length of hospitalization (Lum
et al., 2003).
Corticosteroids have been shown to be no more
effectivethanplaceboornotreatmentforreducing the
number of deaths, the need for blood transfusion or
the number of serious complications (Panpanich et al.,
2006). Randomized controlled study of two treatment
groups treated with or without intravenous immuno-
globulinalsoshowednoeffectinhasteningrecoveryof
platelet counts in patients with secondary dengue
infection (Dimaano et al., 2007).
In contrast, interim data from two randomized
placebo-controlled trials in 47 patients with DHF and
thrombocytopenia have shown increase in platelet
count with anti-D immune globulin (De Castro et al.,
2007). The use of recombinant activated factor VII
(rFVIIa) may also be useful in DHF with massive
bleeding. Effective response was reported in 8/15
(53%) Thai children with grades III and IV DHF
and life-threatening bleeding who were treated with
rFVIIa (Chuansumrit et al., 2005).
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Explosive outbreaks of DHF are often associated with
an increased need for blood components, especially
platelets. When platelets are transfused based on
commonly accepted consensus guidelines, about 8%
of patients with DF and DHF will require platelet
transfusions (Lye et al., 2008). During a large epi-
demic, this will translate to a significant increase in
platelet requirements. D u r i n gt h eh e i g h to ft h e
dengue epidemic in Singapore in 2005, a significant
increase in platelet transfusions was recorded
(Fig. 1), due to increased requirements from DHF
patients.
Inappropriate ordering and use of platelets aggra-
vate these increased requirements and, additionally,
expose the patients to unnecessary transfusion risks.
Chaudhary et al. (2006) report in their study that 35%
of patients received unnecessary prophylactic trans-
fusions, and inappropriate doses were given in 89% of
transfusionepisodesduringaDFepidemic.Inanother
study, 31 of 97 patients still received inappropriate
transfusions despite the presence of platelet trans-
fusion guidelines (Makroo et al., 2007).
In areas where blood services are less well developed
and there is lack of transfusion specialists, lack of
knowledge becomes a major factor leading to inap-
propriate use of blood and blood products. Lum et al.
(2003) recommend that prevention of haemorrhage in
patients with DHF is better achieved through early
detection and management of circulatory imbalance
and shock than through transfusions. The develop-
ment of clear and specific guidelines for platelet and
fresh frozen plasma transfusion in dengue may be
useful in reducing unnecessary use of blood compo-
nents particularly in areas with limited resources.
Wideraccesstomedicalcarefromhealthproviders
with knowledge of DHF can reduce death rates to
less than 1% (World Health Organization, 2008).
Unfortunately, in many developing countries, rural
areas lacksuchaccess,andbloodsupply facilitiesare
often very basic and poorly resourced. As dengue
spreads to rural areas, the challenge of providing
sufficient supplies of safe blood and blood compo-
nents to treat DHF/DSS-associated medical emer-
gencies will place a heavy demand on blood services
in these countries.
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